Manabe Noriaki, Nakajima Atsushi, Odaka Takeo, Haruma Ken
Division of Endoscopy and Ultrasonography, Department of Clinical Pathology and Laboratory Medicine Kawasaki Medical School Okayama Japan.
Department of Gastroenterology and Hepatology Yokohama City University Graduate School of Medicine Yokohama Japan.
JGH Open. 2023 Feb 8;7(3):182-189. doi: 10.1002/jgh3.12870. eCollection 2023 Mar.
A number of basic and clinical studies have confirmed that the traditional Japanese herbal medicine, Daikenchutou (DKT) has a pharmacological effect on cholinergic and serotonergic mechanisms with a favorable safety profile and an improving effect on lower gastrointestinal (GI) symptoms including abdominal pain or bloating. The purpose of this study is to evaluate the efficacy and safety of DKT on chronic constipation.
This multicenter, randomized, placebo-controlled, double-blinded clinical trial enrolled 67 patients with chronic constipation fulfilling Rome III criteria. After a 2-week observation period, 63 patients with persistent symptoms were finally randomized to a 4-week course of treatment with DKT or placebo. The primary endpoint consisted of a global assessment of overall treatment effect (OTE), while the secondary endpoints consisted of improvements in stool consistency, spontaneous bowel movements, lower GI symptoms related to constipation, and quality of life. Factors associated with OTE were also investigated.
After 4 weeks administration of DKT, OTE was significantly higher than placebo. No side effects were observed. Significant improvement in stool consistency and lower GI symptoms was observed in the DKT group. The improvements in lower GI symptoms as well as stool consistency were associated with OTE. OTE was higher in patients with greater improvement in lower GI symptoms with mental component summary scores close to normal before treatment.
DKT was effective and safe in treating chronic constipation, especially in patients having symptoms related to constipation with no impaired mental component summary score.
多项基础和临床研究已证实,传统日本草药大建中汤(DKT)对胆碱能和5-羟色胺能机制具有药理作用,安全性良好,对包括腹痛或腹胀在内的下消化道(GI)症状有改善作用。本研究旨在评估DKT治疗慢性便秘的疗效和安全性。
这项多中心、随机、安慰剂对照、双盲临床试验纳入了67例符合罗马III标准的慢性便秘患者。经过2周的观察期后,63例症状持续的患者最终被随机分为接受DKT或安慰剂治疗4周的疗程。主要终点包括对总体治疗效果(OTE)的整体评估,次要终点包括大便稠度、自主排便、与便秘相关的下消化道症状以及生活质量的改善情况。还研究了与OTE相关的因素。
服用DKT 4周后,OTE显著高于安慰剂。未观察到副作用。DKT组的大便稠度和下消化道症状有显著改善。下消化道症状以及大便稠度的改善与OTE相关。在治疗前心理成分综合评分接近正常且下消化道症状改善较大的患者中,OTE更高。
DKT治疗慢性便秘有效且安全,尤其是对于有便秘相关症状且心理成分综合评分未受损的患者。